COO Sireesh Invests $100K in Hepion Private Placement
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion's COO bought $100,000 of stock in the company's recent private placement, joining the chairman in funding the cash-strapped biotech.
Key Events · Ownership and Investor Activity · CTRVP
-
COO Buys $100K in Private Placement
Appajosyula Sireesh acquired 4,000,000 shares at $0.05 per share for $100,000 on August 3, 2026, in the same placement that raised $3.06 million.
-
Warrants Included
Sireesh also received 2,000,000 warrants with a $0.06 exercise price, expiring August 3, 2031.
-
Insider Cluster
This follows Executive Chairman Vincent LoPriore's $500,000 investment in the same placement, disclosed in a Form 4 filed August 13.
-
Deep Discount to Market
The $0.05 placement price is 38x above today's $0.0013 stock price, reflecting the company's distressed state and reliance on insider capital.
Analysis · CTRVP · Life Sciences
COO Appajosyula Sireesh personally bought 4 million shares at $0.05 each for $100,000 in the same private placement that raised $3.06 million on August 4. He also received 2 million warrants exercisable at $0.06. This is a meaningful insider commitment — roughly 6.7% of the company's tiny $1.5 million market cap — and follows Executive Chairman Vincent LoPriore's $500,000 investment disclosed the same week. The stock trades at $0.0013 today, far below the $0.05 placement price, so the COO is deeply underwater on paper. That gap underscores the company's distress: it needed cash at a price 38x above the current market, and insiders are the ones providing it.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 29% of the 1648 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.